MARKET NEWS

Yingli Pharma Doses First US Patient in Phase 1 Study of YL-13027 for Patients With Advanced Solid Tumors
Oncotelic Therapeutics Receives FDA Clearance for Phase 2 Clinical Trial of OT-101/Pembroluzimab Combination for Mesothelioma (M201)
Crinetics Pharmaceuticals Reports Positive Top-line Results Including Strong Adrenal Suppression from CRN04894 Phase 1 Study Multiple-Ascending Dose Cohorts
Phathom Pharmaceuticals Announces FDA Acceptance for Filing of Vonoprazan NDA for the Treatment of Erosive Esophagitis
Lonza & Israel Biotech Fund Collaboration Framework Agreement to Support Biologics & Small Molecules Development & Manufacture for Portfolio Companies; IBF to Facilitate Access to Israeli Market
GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China

  FEATURED EDITORIAL

 

  COMPANY PROFILE

Intertek’s Pharmaceutical Services laboratory in Whitehouse, NJ, is an FDA- and DEA-registered cGMP-compliant facility, specializing in complex and routine services to support the development of drug products, formulations, medical devices, and drug delivery systems for clients globally. We have pharmaceutical expertise for various GMP and CMC testing, including method development and validation, stability, extractables and leachables, and elemental impurities. Partnering with our Whitehouse facility brings the assurance, confidence, and peace of mind that comes with collaborating with a current good manufacturing practice (cGMP) compliant facility, ensuring that testing will be carried out to the most up-to-date and highest quality standards, preserving the integrity of your products. Click here for more.

  EXCLUSIVE ONLINE CONTENT

Pharmazz Inc. Announces Positive Results of Phase 3 Clinical Trial Evaluating Sovateltide as a Treatment for Acute Cerebral Ischemic Stroke

Pharmazz Inc. Announces Positive Results of Phase 3 Clinical Trial Evaluating Sovateltide as a Treatment for Acute Cerebral Ischemic Stroke

Pharmazz, Inc. recently announced positive topline results of its Phase 3 clinical trial evaluating sovateltide as a treatment for acute ischemic stroke. The data at 90 days showed….

FDA Approves Dermavant’s VTAMA (Tapinarof) Cream, 1% for the Treatment of Plaque Psoriasis in Adults: First Topical Novel Chemical Entity Launched for Psoriasis in the US in 25 Years

FDA Approves Dermavant’s VTAMA (Tapinarof) Cream, 1% for the Treatment of Plaque Psoriasis in Adults: First Topical Novel Chemical Entity Launched for Psoriasis in the US in 25 Years

Dermavant Sciences recently announced the US FDA has approved VTAMA (tapinarof) cream, 1%, an aryl hydrocarbon receptor agonist, indicated for the topical treatment of plaque psoriasis in adults. This approval makes….

Clearmind Medicine & SciSparc Collaboration Yields Positive Results for its Psychedelic Combination Treatment

Clearmind Medicine & SciSparc Collaboration Yields Positive Results for its Psychedelic Combination Treatment

Clearmind Medicine Inc. recently announced positive safety profile results from its joint preclinical trial with SciSparc Ltd. The trial evaluated the proprietary combination of Clearmind’s proprietary psychedelic molecule….

Innoviva to Acquire Entasis Therapeutics

Innoviva to Acquire Entasis Therapeutics

Innoviva, Inc. and Entasis Therapeutics Holdings Inc. recently announced the companies have entered into a definitive merger agreement under which Innoviva is to acquire all….

  WHITEPAPERS & WEBINARS

WEBINAR - Understanding Patch Composition for Effective Transdermal Delivery

WEBINAR - Understanding Patch Composition for Effective Transdermal Delivery

As the advantages of transdermal drug delivery grow, the global market for transdermal patches also is growing. Join DuPont™ Liveo™ Healthcare Solutions and Gattefossé Pharmaceuticals for a complimentary one-hour webinar to explore the current….

On Demand Webinar – Emergent CDMO: High-Speed Manufacturing Solutions for Your Viral Vaccine or Therapeutic

On Demand Webinar – Emergent CDMO: High-Speed Manufacturing Solutions for Your Viral Vaccine or Therapeutic

Emergent and groniger partner to present the benefits and features of the INTEGRA® high-speed aseptic fill line with isolator technology for viral vaccines and therapeutics.

  WHITEPAPERS & WEBINARS

WHITE PAPER: Bring Quality OINDPs to Market Faster Than Ever Before | Proveris Scientific

WHITE PAPER: Bring Quality OINDPs to Market Faster Than Ever Before | Proveris Scientific

The Proveris by Design™ process offers a formalized approach to product development, all the while automating in vitro testing, and streamlining troubleshooting. It is an indispensable tool for successfully developing nasal spray and inhalation drug products as well as critical …

WHITE PAPER - Nanoparticles in Drug Delivery & Photothermal Therapies

WHITE PAPER - Nanoparticles in Drug Delivery & Photothermal Therapies

Nanoparticles offer multi-functional capabilities that include the ability to be tracked within the body, deliver a specific compound at a controlled rate, target a particular location, and remotely kill cells once in place due to which their use as drug …

WHITE PAPER: Selecting In-Vitro Dissolution Methodologies for Amorphous Solid Dispersions

WHITE PAPER: Selecting In-Vitro Dissolution Methodologies for Amorphous Solid Dispersions

Achieving good in vivo performance is a key attribute for ensuring safety and efficacy of oral solid dosage (OSD) forms intended for systemic delivery. Yet, new drug targets and mecha­nisms of action continue to drive drug candidates’ phys­ical properties toward …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

June 8 – Injection Devices
June 15 – Parenteral Contract Manufacturing